SummaryThis is a randomised, open label study recruiting postmenopausal women with early-stage ER+, PR+, HER-negative breast cancer. The trial has three arms, each running for 14 days. Participants will receive treatment after diagnosis but prior to surgery. In Arm 1, participants will receive letrozole 2.5mg, administered orally once daily. In Arm 2, participants will receive letrozole 2.5mg and prometrium 300mg, administered orally once daily. In Arm 3, participants will receive tamoxifen 20mg and prometrium 300mg, administered orally once daily.
This trial is treating patients with early stage ER+, PR+, HER-negative breast cancer.
Use the hyperlinks, where available to access additional clinical trial information.
St. Vincent's Hospital-Manhattan
A Window of Opportunity Study of Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Hormone Receptor-positive Breast Cancer.